Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM159PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 7531.085 | 0.1444 | 0.1540 | 3.5188 | |
| SUM159PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 7531.085 | 0.0005 | -0.7688 | 3.5188 | |
| SUM185PE | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7532.084 | 0.8948 | 0.7334 | 0.7770 | |
| SUM185PE | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7532.084 | 0.9712 | 0.9261 | 0.7770 | |
| SUM185PE | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7532.084 | 0.9794 | 0.9471 | 0.7770 | |
| SUM185PE | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7532.084 | 0.9141 | 0.7817 | 0.7770 | |
| SUM185PE | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7532.084 | 0.8389 | 0.5953 | 0.7770 | |
| SUM185PE | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7532.084 | 0.6548 | 0.1598 | 0.7770 | |
| SUM185PE | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7532.084 | 0.2872 | -0.5984 | 0.7770 | |
| SUM185PE | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7532.084 | 0.6944 | 0.2508 | 0.7770 | |
| SUM185PE | TNBC | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7532.084 | 0.1612 | -0.8090 | 0.7770 | |
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7533.084 | 0.9723 | 0.9467 | 1.0396 | |
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7533.084 | 1.0111 | 1.0213 | 1.0396 | |
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7533.084 | 0.9804 | 0.9623 | 1.0396 | |
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7533.084 | 1.0373 | 1.0716 | 1.0396 | |
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7533.084 | 1.0045 | 1.0087 | 1.0396 | |
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7533.084 | 0.8765 | 0.7619 | 1.0396 | |
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7533.084 | 0.7811 | 0.5769 | 1.0396 | |
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7533.084 | 0.6096 | 0.2423 | 1.0396 | |
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7533.084 | 0.3922 | -0.1872 | 1.0396 | |
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7534.084 | 0.9806 | 0.9564 | 0.8905 | |
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7534.084 | 1.0339 | 1.0763 | 0.8905 | |
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7534.084 | 0.9993 | 0.9984 | 0.8905 | |
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7534.084 | 0.9883 | 0.9737 | 0.8905 | |
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7534.084 | 0.9141 | 0.8080 | 0.8905 |